Inhibition of basigin expression in glioblastoma cell line via antisense RNA reduces tumor cell invasion and angiogenesis

被引:92
作者
Liang, QC
Xiong, H
Gao, GD [1 ]
Xiong, KH
Wang, XL
Zhao, ZW
Zhang, H
Li, YL
机构
[1] Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian 710038, Peoples R China
[2] Fourth Mil Med Univ, Cell Engn Res Ctr, State Key Lab Canc Biol, Xian 710038, Peoples R China
[3] Fourth Mil Med Univ, Dept Anat, Xian 710038, Peoples R China
[4] Fourth Mil Med Univ, KK Leung Brain Res Ctr, State Key Lab Neurosci, Xian 710038, Peoples R China
关键词
angiogenesis; antisense RNA; basigin; glioblastoma; invasion; matrix metalloproteinase;
D O I
10.4161/cbt.4.7.1828
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Basigin/CD147, also named extracelluar matrix metalloproteinase inducer (EMMPRIN), has been implicated in playing very important roles in several aspects of tumor progression. In this study, we examined the inhibitory effects of antisense RNA of CD147 on invasion and angiogenesis of human glioblastoma U251 cells in vitro. The U251 cell line was transfected by a plasmid containing antisense CD147 cDNA. Gelatin zymography was used to determine the effect on reducing secretions of MMP-2 and MMP- 9 of the transfected cells. Boyden chamber was employed to test the invasion of U251 cells in vitro. We found that downregulation of CD147 resulted in reducing secretions of MMP-2, MMP-9, and VEGF. Moreover, the invasion of stable antisense transfectants was inhibited. Wound-induced migration assay also showed decreased migration in stable antisense transfectants compare to parental- and empty vector-transfected cells. Taken together, these results provide evidence that invasion of human glioblastoma cells can be inhibited by antisense RNA of CD147. Basigin/ CD147 may be used as a potential target of drugs for anti-invasion and metastasis of human glioblastoma cells.
引用
收藏
页码:759 / 762
页数:4
相关论文
共 30 条
[1]
Adjei AA, 2003, CLIN CANCER RES, V9, P115
[2]
Agrawal S, 2002, INT J ONCOL, V21, P65
[3]
Belfort R, 2002, AM J OPHTHALMOL, V133, P467
[4]
BISWAS C, 1995, CANCER RES, V55, P434
[5]
Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.0.CO
[6]
2-#
[7]
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report [J].
Coudert, B ;
Anthoney, A ;
Fiedler, W ;
Droz, JP ;
Dieras, V ;
Borner, M ;
Smyth, JF ;
Morant, R ;
de Vries, MJ ;
Roelvink, M ;
Fumoleau, P .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (17) :2194-2198
[8]
Cripps MC, 2002, CLIN CANCER RES, V8, P2188
[9]
Cunningham CC, 2001, CANCER, V92, P1265, DOI 10.1002/1097-0142(20010901)92:5<1265::AID-CNCR1447>3.0.CO
[10]
2-5